Last spring, GlaxoSmithKline published a five-year research plan for a new class of brain-altering therapeutics that, at first glance, one might assume a major pharma company would not be so enthusiastic about supporting. Why? Because these therapies, called “bioelectronics” are actually tiny implantable devices that could very well supplant drugs to treat everything from inflammatory diseases to cancer.
Hey, check out all the engineering jobs. Post your resume today!
